PHARM MANUF/DISTR DIV - FSA

The solicitation SPE2D2-25-R-0014, issued by the Department of Defense’s Medical Supply Chain FSGB under the NAICS code 325412 for pharmaceutical manufacturing and distribution, seeks offers for the supply of specific valsartan and hydrochlorothiazide tablet formulations in 90-count bottles, with base quantities and four option years clearly defined for each line item. Proposals must be submitted electronically through the DIBBS portal by the deadline of August 13, 2026, and are evaluated under a Lowest Price Technically Acceptable (LPTA) framework, where technical compliance and past performance are binary pass/fail criteria, and award goes to the lowest-priced proposal that meets all non-price requirements. The contract requires full adherence to FDA regulations, including current Good Manufacturing Practices, valid National Drug Codes, and therapeutic equivalence standards, with product labeling and packaging subject to strict commercial standards such as GS1-128 or HIBCC bar codes, child-proof closures, and dimensional constraints on bottles including a minimum 100cc volume and labeling area requirements. Packaging must exclude glass, ensure compatibility with automated dispensing systems, and maintain bar code readability throughout transportation and storage without placement across blister pack perforations. Deviations from standard FAR and DFARS clauses are actively applied, particularly around cybersecurity, subcontractor restrictions, reporting of executive compensation, small business representations, and prohibitions on covered telecommunications equipment, necessitating mandatory representations and certifications through SAM.gov including Unique Entity Identifier and CAGE code. All performance locations—domestic and foreign—must be disclosed, and products must be delivered to DLA and VA Prime Vendor distribution centers under FOB Destination terms, with inspection occurring at the point of origin to verify facility compliance and at the destination upon receipt. The contract includes an option to extend the term up to four additional years and incorporates clauses mandating a code of business ethics, prohibitions on confidentiality agreements that conceal misconduct, and requirements for dispute resolution via alternative methods. Pricing is to be submitted in separate volumes, with non-price documentation including FDA violation disclosures and signed SF 1449, while pricing volume must list unit costs per bottle for base and all option years; however, no estimated contract value can be determined due to absence of pricing data in the solicitation. Payment and administrative details including the contracting officer, contracting officer’s representative, and appropriation accounting data will be finalized upon award.